Results 21 to 30 of about 723,552 (238)

On BCG Vaccine Protection from COVID-19: A Review

SN Comprehensive Clinical Medicine, 2021
Bacille Calmette-Guérin (BCG) vaccine has been globally used to protect infants against tuberculosis (TB) for about a century. This vaccine has been shown to provide some degree of non-specific protection from other respiratory tract infections.
N. Bagheri, H. Montazeri
semanticscholar   +1 more source

Differential COVID-19-attributable mortality and BCG vaccine use in countries

medRxiv, 2020
While mortality attributable to COVID-19 has devastated global health systems and economies, striking regional differences have been observed. The Bacille Calmette Guerin (BCG) vaccine has previously been shown to have non-specific protective effects on ...
A. Shet, D. Ray, N. Malavige, M. Santosham, N. Bar-Zeev   +4 more
semanticscholar   +1 more source

Procedure for preparation, certification, and storage of a seed lot of the Mycobacterium bovis BCG-I (Russia) vaccine strain

Биопрепараты: Профилактика, диагностика, лечение, 2022
To date, the Bacillus Calmette–Guérin (BCG) vaccine has been the only medicinal product for active mass childhood immunisation against tuberculosis in the Russian Federation.
D. T. Levi, R. I. Ludannyy, Yu. I. Obukhov, A. A. Savina, A. A. Alesina, N. V. Aleksandrova   +5 more
doaj   +1 more source

Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. [PDF]

PLoS ONE, 2009
Recombinant adenovirus-vectored (Ad) tuberculosis (TB) vaccine platform has demonstrated great potential to be used either as a stand-alone or a boost vaccine in murine models.
Zhou Xing, Christine T McFarland, Jean-Michel Sallenave, Angelo Izzo, Jun Wang, David N McMurray   +5 more
doaj   +1 more source

Non-specific effects of BCG vaccine on viral infections.

Clinical Microbiology and Infection, 2019
BACKGROUND Some strains of Bacillus Calmette-Guérin (BCG) vaccine not only confer protection against disseminated forms of tuberculosis, but also reduce all-cause mortality by the induction of protection against infections with non-related pathogens ...
S. Moorlag, R. Arts, R. Crevel, M. Netea, M. Netea   +4 more
semanticscholar   +1 more source

Outbreak of Bacille Calmette-Guérin-related lymphadenitis in Saudi children at a university hospital after a change in the strain of vaccine

Annals of Saudi Medicine, 2012
BACKGROUND AND OBJECTIVES: Bacille Calmette-Guérin (BCG) vaccination is part of the expanded program of vaccination in Saudi Arabia. Lymphadenitis is the most common complication of the BCG vaccine.
Abdulkarim Abdullah Alrabiaah, Sarah Suliman Alsubaie, Elham Issa Bukhari, Ashry Gad, Fahad Abdullah Alzamel   +4 more
doaj   +1 more source

Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy. [PDF]

PLoS Neglected Tropical Diseases, 2016
Buruli ulcer (BU) vaccine design faces similar challenges to those observed during development of prophylactic tuberculosis treatments. Multiple BU vaccine candidates, based upon Mycobacterium bovis BCG, altered Mycobacterium ulcerans (MU) cells ...
Bryan E Hart, Sunhee Lee
doaj   +1 more source

Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine

mBio, 2016
Mycobacterium bovis BCG is the only available vaccine for protection against tuberculosis (TB). While BCG protects children from severe disease, it has little impact on pulmonary disease in adults. A recombinant BCG vaccine BCG ΔureC::hly (strain VPM1002)
Helen A. Fletcher
doaj   +1 more source

Bacillus Calmette-Guérin (BCG) vaccine: A global assessment of demand and supply balance

Vaccine, 2018
Over the past decade, several countries across all regions, income groups and procurement methods have been unable to secure sufficient BCG vaccine supply.
Tania Cernuschi, S. Malvolti, E. Nickels, M. Friede   +3 more
semanticscholar   +1 more source

Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial

EClinicalMedicine, 2020
Background Respiratory syncytial virus (RSV) is responsible for most respiratory tract infections and hospitalizations in infants and represents a significant economic burden for public health. The development of a safe, effective, and affordable vaccine
K. Abarca, Emma Rey-Jurado, N. Muñoz-Durango, Y. Vázquez, J. Soto, N. Gálvez, Javier Valdés-Ferrada, C. Iturriaga, M. Urzúa, A. Borzutzky, J. Cerda, L. Villarroel, V. Madrid, P. González, J. V. González-Aramundiz, S. Bueno, A. Kalergis   +16 more
semanticscholar   +1 more source